1Langer SW.Dexrazoxane for anthracycline extravasation[J].Expert Rev Anticancer Ther,2007,7(8):1081-1088.
2Swain SM,Whaley FS,Gerber MC,et al.Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicincontaining therapy[J].J Clin Oncol,1997,15(4):1333-1340.
3Classen S,Olland S,Berger JM,et al.Structure of the topoisemerase ⅡATPase region and its mechamism of inhibition by the chemotherapeutic agent ICRF-187[J].Proc Natl Acad Sci,2003,100(19):10629-10634.
4Hasinoff BB.Dexrazoxane use in the prevention of anthracycline extravasation injury[J].Future Oncol,2006,2(1):15-20.
5Langer SW,Sehested M,Jensen PB.Treatmentof anthracycline extravasation with dexrazoxane[J].Clin Cancer Res,2000,6(9):3680-3686.
6Langer SW,Thougaard AV,Sehested M,et al.Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone[J].Cancer Chemother Pharmacol,2006,57(1):125-128.
7Mouridsen HT,Langer SW,Buter J,et al.Treatment of anthracyclin extravasation with savene(dexrazoxane):results from two prospective clinical multicentre studies[J].Ann Oncol,2007,18(3):546-550.
8Schulmeister L.Totect:a new agent for treating anthracyclin extravasation[J].Clin J Oncol Nurs,2007,11(3):387-395.
9Langer SW,Jensen PB,Sehested M.Other uses of dexrazoxane:savene,the first proven antidote against anthracycline extravasation injuries[J].Cardiovasc Taxicol,2007,7(2):151-153.
10Marry M,Espie M,Llombart A,et al.Multicenter randomized phase Ⅲ study of the cardioprotective effect of dexrazoxane (cardioxane) in advanced/metastatic breat cancer patients treated with anthracycline-hased chemotherapy[J].Ann Oncol,2006,17(4):614-622.
